Back to DatabaseNot FDA Approved
PNC-27
Also known as: PNC27, p53-Derived Peptide, Antitumor Peptide PNC-27
Immune Modulation
Preclinical
PNC-27 is an experimental anti-cancer peptide derived from the p53 tumor suppressor protein. It is designed to selectively target and kill cancer cells by exploiting the aberrant membrane expression of HDM-2 (the p53-binding protein) that is found on the surface of cancer cells but not normal cells. Research is entirely preclinical — no human trials completed.
Regulatory & Approval Status
PNC-27 is an experimental anti-cancer peptide currently limited to preclinical research and has not entered human clinical trials or received FDA approval.
Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.